Abstract:<h3 class="Heading">Background</h3><p class="Para">Biotherapeutics are protein products generated using recombinant DNA technology and manufactured in prokaryotic or eukaryotic cells. It is often said that "the process is the product" and thereby the effect of the manufacturing process is etched on the final product in the form of its heterogeneity. For any biotherapeutic, the acceptable range of the critical quality attributes is defined based on the expected impact of a specific variation on the product stability, safety, and efficacy. For a biosimilar to receive regulatory approval, the manufacturer must demonstrate analytical and clinical comparability with the originator product. As this is mandatory, every biosimilar manufacturer performs this exercise for each biosimilar product under development. However, few reports of thorough evaluation of the quality of biosimilar products are available in the literature.</p><h3 class="Heading">Objective</h3><p class="Para">We examined the structural and functional comparability of biosimilars of trastuzumab, a humanized monoclonal antibody biotherapeutic. The originator product, Herclon (Roche), was compared with four marketed biosimilars: Trasturel from Reliance Life Sciences, Canmab from Biocon, Vivitra from Zydus Ingenia, Hertraz from Mylan.</p><h3 class="Heading">Methods</h3><p class="Para">Structural comparability was established using mass spectrometry and spectroscopic techniques such as Fourier transform infrared spectroscopy, differential light scattering, circular dichroism, and fluorescence spectroscopy. Stability was compared by performing accelerated thermal stress studies. Functional comparability was established via surface plasmon resonance and biological assays such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.</p><h3 class="Heading">Results</h3><p class="Para">With respect to comparability, one biosimilar exhibited significant differences in multiple attributes, such as lower percentage of monomer content and main charge variant species, lower percentage of aglycosylated glycoform G0, and lower estimated potency values.</p><h3 class="Heading">Conclusions</h3><p class="Para">Overall, the results indicated general similarity with respect to structure and function, but we found variations with respect to size heterogeneity, charge heterogeneity, and glycosylation pattern in each of the biosimilars.</p>

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the structural and functional comparability between trastuzumab biosimilars and the original product. Specifically, the researchers conducted a detailed analysis of the structural and functional characteristics of four marketed trastuzumab biosimilars and compared them with the original product Herclon (produced by Roche Pharmaceuticals). Through this research, the aim is to verify whether these biosimilars are comparable to the original product in terms of key quality attributes, thereby supporting the safety and effectiveness of their clinical applications. ### Research Background Biotherapeutic drugs are protein products produced in prokaryotic or eukaryotic cells using recombinant DNA technology. Due to the concept of "process is product", the influence of the manufacturing process will be reflected in the final product in the form of product heterogeneity. For any biotherapeutic drug, the acceptable range of its key quality attributes is defined based on the expected impact of specific variations on product stability, safety, and effectiveness. To obtain regulatory approval, biosimilar manufacturers must demonstrate the analytical and clinical comparability of their products with the original product. However, comprehensive assessment reports on biosimilar product quality are rare in the literature. ### Research Purpose The purpose of this study is to evaluate the structural and functional comparability of trastuzumab biosimilars. The research objects include the original product Herclon (Roche Pharmaceuticals) and four marketed biosimilars: Trasturel by Reliance Life Sciences, Canmab by Biocon, Vivitra by Zydus Ingenia, and Hertraz by Mylan. ### Methods - **Structural Comparability**: Evaluated using techniques such as mass spectrometry, Fourier - transform infrared spectroscopy, differential light scattering, circular dichroism, and fluorescence spectroscopy. - **Stability**: Evaluated through accelerated thermal stress experiments. - **Function Comparability**: Evaluated through surface plasmon resonance and biological experiments (such as antibody - dependent cell - mediated cytotoxicity ADCC and complement - dependent cell - cytotoxicity CDC). ### Results Overall, the research results show that these biosimilars are similar to the original product in terms of structure and function, but there are differences in aspects such as size heterogeneity, charge heterogeneity, and glycosylation patterns. Among them, one biosimilar shows significant differences in multiple attributes, such as a lower monomer content, a lower percentage of the main charge variant species, a lower percentage of the non - glycosylated glycoform G0, and a lower estimated potency value. ### Conclusions Although these biosimilars are similar to the original product in terms of structure and function, each biosimilar has differences in terms of size heterogeneity, charge heterogeneity, and glycosylation patterns. These findings provide information on the quality of biotherapeutic products in the Indian market for patients, regulatory agencies, and other stakeholders.

Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study